Skip to main content
Clinical Trials/ACTRN12616001482459
ACTRN12616001482459
Completed
未知

Assessment of a Non-Invasive System to Detect Changes in Physiological Tremor in Children and Adolescents with Type 1 Diabetes Mellitus.

Firefly Health Pty Ltd0 sites20 target enrollmentOctober 25, 2016

Overview

Phase
未知
Intervention
Not specified
Conditions
Hypoglycaemia.
Sponsor
Firefly Health Pty Ltd
Enrollment
20
Status
Completed
Last Updated
6 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
October 25, 2016
End Date
TBD
Last Updated
6 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Firefly Health Pty Ltd

Eligibility Criteria

Inclusion Criteria

  • \*Have voluntarily given written informed consent to participate in the study.
  • \*Are male or female aged 5 years up to 18 years (inclusive).
  • \*Have type 1 diabetes (as determined by the Principal Investigator or delegate).
  • \*On no medication that may exacerbate or reduce the physiological tremor (as determined by the Principal Investigator or delegate).
  • \*Can wear both the CGMS and TIP3 Firefly Monitoring Device.
  • \*Participant is willing to perform at least 4 capillary blood glucose readings each day of study.
  • \*Participant and/or their caregiver/guardian is willing to keep the Diary as per protocol requirements.
  • \*Can follow the protocol for the CGM and the glucose meter.

Exclusion Criteria

  • \*Are unwilling to wear the clinical monitoring devices for the duration of the study
  • \*Any history of cerebro\-vascular disease, central or peripheral neurological disease, idiopathic tremors, primary muscle disease, ischaemic muscle disease.
  • \*On medications that may affect muscle tremor.
  • \*Excessive use of alcohol (as determined by the Principal Investigator or his delegate).
  • \*Illicit drug use.
  • \*Dermatological conditions (e.g. psoriasis) involving the region of CGM insertion.
  • \*Current use of a CGM with alarms or plans to start using one during the study.
  • \*Unable to follow the protocols.

Outcomes

Primary Outcomes

Not specified

Similar Trials